UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group - PubMed (original) (raw)

Clinical Trial

UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group

No authors listed. Diabetes Care. 1998 Jan.

Abstract

Objective: To assess the efficacy over 3 years of the addition of metformin to maximum sulfonylurea therapy in type 2 diabetes.

Research design and methods: This multicenter randomized open-controlled trial was conducted in outpatient diabetes clinics in 15 U.K. hospitals. A total of 591 subjects who had already been randomly allocated to sulfonylurea therapy were taking maximum doses with suboptimal glycemic control, i.e., raised fasting plasma glucose (FPG) concentrations of 6-15 mmol/l but no significant hyperglycemic symptoms. The main outcome measures included FPG, glycated hemoglobin, protocol-defined marked hyperglycemia, body weight, blood pressure, fasting plasma lipids, compliance, and hypoglycemia and other side effects.

Results: After the addition of metformin, FPG concentrations decreased by mean (95% CI) -0.47 (-0.82 to -0.13) mmol/l over 3 years compared with an increase of 0.44 (0.07-0.81) mmol/l in subjects on sulfonylurea alone (P < 0.00001). Median FPG concentrations at 3 years were 8.6 vs. 9.9 mmol/l, respectively (P < 0.00001), and HbA1c values were 7.5 and 8.1%, respectively (P = 0.006). Adjustment for baseline BMI or FPG concentration did not affect response to therapy. Only 7% of those allocated to sulfonylurea plus metformin developed protocol-defined marked hyperglycemia compared with 36% of those allocated to sulfonylurea alone (P < 0.0001). Fasting plasma lipids, body weight, and blood pressure did not change significantly. The incidence of hypoglycemic episodes did not differ between groups: 4% on sulfonylurea plus metformin and 2% on sulfonylurea alone (NS).

Conclusions: Early addition of metformin improved glycemic control in patients with suboptimal glycemic control while taking maximum sulfonylurea therapy, irrespective of obesity or baseline FPG concentrations.

PubMed Disclaimer

Cited by

Vicious cycle between severity of childhood obesity and pandemic: Potential impact of metformin.
Samur BM, Samur TG, Gul-Sir U, Hatipoglu N. Samur BM, et al. Obes Med. 2022 Aug;33:100433. doi: 10.1016/j.obmed.2022.100433. Epub 2022 Jun 13. Obes Med. 2022. PMID: 35720680 Free PMC article.
Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis.
Alsugair HA, Alshugair IF, Alharbi TJ, Bin Rsheed AM, Tourkmani AM, Al-Madani W. Alsugair HA, et al. Healthcare (Basel). 2021 Aug 30;9(9):1125. doi: 10.3390/healthcare9091125. Healthcare (Basel). 2021. PMID: 34574899 Free PMC article. Review.
Erectile dysfunction and diabetes: A melting pot of circumstances and treatments.
Defeudis G, Mazzilli R, Tenuta M, Rossini G, Zamponi V, Olana S, Faggiano A, Pozzilli P, Isidori AM, Gianfrilli D. Defeudis G, et al. Diabetes Metab Res Rev. 2022 Feb;38(2):e3494. doi: 10.1002/dmrr.3494. Epub 2021 Sep 21. Diabetes Metab Res Rev. 2022. PMID: 34514697 Free PMC article. Review.
A Comparison Between the Therapeutic Effect of Metformin Alone versus a Combination Therapy with Insulin in Uncontrolled, Non-Adherence Patients with Type 2 Diabetes: Six Months Follow-Up.
Paczkowska A, Hoffmann K, Michalak M, Bryl W, Kopciuch D, Zaprutko T, Ratajczak P, Nowakowska E, Kus K. Paczkowska A, et al. Diabetes Metab Syndr Obes. 2021 Jul 14;14:3243-3252. doi: 10.2147/DMSO.S317659. eCollection 2021. Diabetes Metab Syndr Obes. 2021. PMID: 34285531 Free PMC article.
Effects of metformin on endothelial health and erectile dysfunction.
Patel JP, Lee EH, Mena CI, Walker CN. Patel JP, et al. Transl Androl Urol. 2017 Jun;6(3):556-565. doi: 10.21037/tau.2017.03.52. Transl Androl Urol. 2017. PMID: 28725599 Free PMC article. Review.

UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group - PubMed (original) (raw)